Europe tightens safety warnings on alopecia areata drug Litfulo

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has recommended strengthening the safety warnings for Litfulo (ritlecitinib tosylate, Pfizer), a JAK inhibitor approved for severe alopecia areata in adults and adolescents aged 12 and older. The update aligns Litfulo's label with other JAK inhibitors, which carry well-established risks for serious side effects.

A new boxed warning will specify that Litfulo should only be used in certain high-risk patients when no suitable treatment alternatives are available. The recommendation follows a review of clinical trial data, medical literature, and post-marketing safety reports.

Key Takeaways:

• High-risk groups requiring caution include patients aged 65+, those with cardiovascular risk factors, long-term smokers, and those at elevated cancer risk
• Patients should also be monitored for pulmonary embolism and deep vein thromboembolism
• Platelet and lymphocyte counts must be checked before treatment, at 4 weeks, and periodically thereafter
• If no therapeutic benefit is seen after 36 weeks, discontinuation should be considered

Why it matters: Alopecia areata affects roughly 2% of people over their lifetime and carries a significant psychological burden. While Litfulo offers meaningful hair regrowth for many patients, these strengthened warnings ensure clinicians weigh serious systemic risks — particularly for vulnerable populations — before prescribing.